Safety and efficacy of mavacamten for treatment of hypertrophic cardiomyopathy: a systematic review and meta-analysis of randomized clinical trials

Safety and efficacy of mavacamten for treatment of hypertrophic cardiomyopathy: a systematic review and meta-analysis of randomized clinical trials

Abstract Background Mavacamten, an allosteric myosin inhibitor, is considered to be a promising drug for the treatment of hypertrophic cardiomyopathy (HCM). This meta-analysis aimed to explore the safety and efficacy of mavacamten in HCM patients. Main body A total number of 539 patients were enroll...

Full description

Bibliographic Details
Main Authors: Mehrdad Rabiee Rad, Ghazal Ghasempour Dabaghi, Danial Habibi
Format: Article
Language:English
Published: SpringerOpen 2023-01-01
Series:The Egyptian Heart Journal
Subjects:
Hypertrophic cardiomyopathy
Mavacamten
HCM
HOCM
Online Access:https://doi.org/10.1186/s43044-023-00328-7

Similar Items

Similar Items